iBio, Inc. Common Stock (IBIO) Stock Price

IBIOStock

$1.36+64.83%52W

Market Cap$67.56M

P/E—

PEG Ratio—

Div yield—

Beta1.25

IBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-56.87%

Price vs S&P 500 (4W)-5.77%

VGM Score32.36

Book Value / Share (Quarterly)$2.24

P/TBV (Annual)1.02x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-40.30%

Cash Flow / Share (Quarterly)$-0.64

Price vs S&P 500 (YTD)-42.35%

Gross Margin (TTM)52.10%

Net Profit Margin (TTM)-3049.40%

EPS (TTM)$-0.83

10-Day Avg Trading Volume0.91M

EPS Excl Extra (TTM)$-0.83

Revenue Growth (5Y)-24.59%

EPS (Annual)$-1.75

ROI (Annual)-221.12%

Gross Margin (Annual)38.40%

Net Profit Margin (5Y Avg)-4064.26%

Cash / Share (Quarterly)$2.17

ROA (Last FY)-157.79%

Revenue Growth TTM (YoY)-20.00%

EBITD / Share (TTM)$-0.52

ROE (5Y Avg)-251.07%

Operating Margin (TTM)-3113.60%

Cash Flow / Share (Annual)$-36.87

P/B Ratio0.90x

P/B Ratio (Quarterly)0.85x

Net Income / Employee (Annual)$-918,800

EV / Revenue (TTM)43.84x

Net Interest Coverage (TTM)-9.05x

ROA (TTM)-46.48%

EPS Incl Extra (Annual)$-1.75

Current Ratio (Annual)1.22x

Quick Ratio (Quarterly)11.50x

3-Month Avg Trading Volume0.89M

52-Week Price Return64.83%

Revenue / Employee (TTM)$15,000

Tangible BV / Share (Quarterly)$2.19

P/S Ratio (Annual)173.88x

Asset Turnover (Annual)0.02x

52-Week High$3.82

Operating Margin (5Y Avg)-3157.90%

EPS Excl Extra (Annual)$-1.75

CapEx CAGR (5Y)-57.47%

Tangible BV CAGR (5Y)-7.29%

26-Week Price Return-44.94%

Quick Ratio (Annual)1.19x

13-Week Price Return-29.53%

Total Debt / Equity (Annual)0.91x

Current Ratio (Quarterly)11.88x

Enterprise Value$21.92M

Revenue / Share Growth (5Y)-68.67%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-50.39%

Revenue / Employee (Annual)$20,000

Inventory Turnover (Annual)3.65x

Pretax Margin (Annual)-4594.25%

Cash / Share (Annual)$4.30

3-Month Return Std Dev48.90%

Gross Margin (5Y Avg)50.77%

Net Income / Employee (TTM)$-1,380,300

ROE (Last FY)-422.14%

Net Interest Coverage (Annual)-291.78x

EPS Basic Excl Extra (Annual)$-1.75

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.83

Receivables Turnover (Annual)0.00x

ROI (TTM)-53.44%

P/S Ratio (TTM)139.10x

Pretax Margin (5Y Avg)-3001.85%

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$10.00

Price vs S&P 500 (52W)46.27%

Year-to-Date Return-29.53%

5-Day Price Return-4.23%

EPS Normalized (Annual)$-1.75

ROA (5Y Avg)-59.82%

Net Profit Margin (Annual)-4594.25%

Month-to-Date Return-2.86%

Cash Flow / Share (TTM)$-1.62

EBITD / Share (Annual)$-1.70

Operating Margin (Annual)-4650.50%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-75.76%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.83

P/TBV (Quarterly)0.87x

P/B Ratio (Annual)0.67x

Inventory Turnover (TTM)1.98x

Pretax Margin (TTM)-3049.40%

Book Value / Share (Annual)$15.40

Price vs S&P 500 (13W)-31.49%

Beta1.25x

Revenue / Share (TTM)$0.00

ROE (TTM)-53.86%

52-Week Low$0.77

vGradeD

gGradeF

mGradeD

vgmGradeD

IBIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Feb 10, 2026	-$0.07	-$0.09	-38.46%(-$0.02)
Q3 2025	Nov 12, 2025	-$0.07	-$0.11	-50.01%(-$0.04)
Q2 2025	Sep 5, 2025	-$0.36	-$0.32	+12.33%(+$0.04)

IBIO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.21

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
IBIOiBio, Inc. Common Stock	D	F	D	$1.36
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About iBio, Inc. Common Stock

iBio Inc is a preclinical-stage biotechnology company that uses artificial intelligence to develop precision antibodies and provide contract manufacturing services. The company's AI-driven platform employs epitope-steering and monoclonal antibody optimization to reduce development risk and accelerate time to clinic.